Celanese (CE)
NYSEMaterialsChemicalsSnapshot 2026-09-14
$44.78-2.84%
Close 2026-09-14 · 1-day change
NYSEMaterialsChemicalsSnapshot 2026-09-14
Research Workspace
Put CE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Cash from operating activities reaches at least $76M in Q1 2026: Q1 FY2026 operating cash flow not reported; Q2 FY2026 EPS beat consensus by 10.9%.
View ThesisRevenue is contracting — down about 2% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens weak on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 38% in its worst 12-month stretch.
View RiskCelanese's growth relies on enhancing cash flow generation and deleveraging. Revenue grew 18% year over year, and the last quarter beat expectations. It trades at 8.7× P/E versus a peer median of 17×, indicating the price reflects less growth than forecasted. A specific risk is the 35% probability of a miss in the next quarter. Peer multiples imply a price about 46% above where it trades. This read is provisional; the thesis is on watch.
Trailing returns as of 2026-09-14. CE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering CE (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for CE in the last 4 months.
Continue this research
Compare CE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 8 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put CE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Enhance cash flow generation and deleveraging
Sale enhances cash flow and supports deleveraging efforts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $44.78
The last 12 months of price, then the range of analyst 12-month targets from today’s $44.78.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Guidance issues may hinder growth and cash flow objectives.
Guidance issues may hinder growth and cash flow objectives.
Dismissal of damages claim supports legal standing and reduces risk.
Advances: Enhance cash flow generation and deleveraging
Targets significant cash flow and divestitures align with objectives.
Threatens: Enhance cash from operating activities
Earnings beat but share decline raises cash flow concerns.
